Drug Trial Radar · NCT00226707
Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis
Last checked: Nov 19, 2026Latest source record: Feb 15, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
652
Actual
Start
Jul 2004
Primary completion
Not stated
Study completion Mar 2005
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 27, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
Topical steroids are standard of care for Chronic Hand Dermatitis, but long-term use is associated with adverse effects. This study will assess the efficacy and safety of pimecrolimus cream 1% in patients with mild-to-moderate chronic hand dermatitis.
Conditions
- Chronic Hand Dermatitis
Interventions
Pimecrolimus Cream 1%Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigators Global Assessment (IGA) of the target hand at day 43 or at time of early discontinuation.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.